Cisplatin, doxorubicin
and cytoxan (under clinical evaluation)
Pre-operative Cisplatin and vindesine with or without mitomycin-C (under clinical
evaluation)
Carboplatin-containing regimens
Hormones (not useful for lung cancer)
Biological Response Modifiers (not proven to be useful thus far)
All patients should receive
combination chemotherapy regardless of the extent of disease.
VPP--Etoposide (VP-16) and cisplatin, with or without other agents such as
vincristine, methotrexate and adriamycin.
CAV--Cytoxan, adriamycin, and vincristine
CAVP-16--Cytoxan, adriamycin and etoposide
Cytoxan, methotrexate and lomustine
Cytoxan, methotrexate, lomustine and vincristine
Cytoxan, adriamycin, etoposide and vincristine
CEV--Cytoxan, etoposide, and vincristine
Hormones (not useful for lung cancer)
Biological Response Modifiers (not proven to be useful thus far)
Endoscopic photodynamic therapy (under clinical evaluation for non-small cell lung cancer)
Cancer Vaccines: Cancer vaccines are still in the experimental phase and are not coded in this data item. They may be coded in the field Other Therapy. Currently clinical trials use cancer vaccines for brain, breast, colon, kidney, lung, melanoma and ovary.
BMT Autologous: Uses the patient’s own bone marrow and/or stem cells. The tumor cells are filtered out and the purified blood and stem cells are returned to the patient.
Note: Used for breast cancer, lymphoma, leukemia, aplastic anemia, myeloma, germ cell tumors, ovarian cancer, and small cell lung cancer.
To learn more about chemotherapy, click here to see the Cancer Treatment module.